AU2014240950B2 - Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders - Google Patents

Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders Download PDF

Info

Publication number
AU2014240950B2
AU2014240950B2 AU2014240950A AU2014240950A AU2014240950B2 AU 2014240950 B2 AU2014240950 B2 AU 2014240950B2 AU 2014240950 A AU2014240950 A AU 2014240950A AU 2014240950 A AU2014240950 A AU 2014240950A AU 2014240950 B2 AU2014240950 B2 AU 2014240950B2
Authority
AU
Australia
Prior art keywords
formula
compound
cancer
compounds
furan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014240950A
Other languages
English (en)
Other versions
AU2014240950A1 (en
Inventor
Richard Huber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AVOSCIENCE LLC
Original Assignee
AVOSCIENCE LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVOSCIENCE LLC filed Critical AVOSCIENCE LLC
Publication of AU2014240950A1 publication Critical patent/AU2014240950A1/en
Application granted granted Critical
Publication of AU2014240950B2 publication Critical patent/AU2014240950B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
AU2014240950A 2013-03-29 2014-03-28 Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders Ceased AU2014240950B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361853163P 2013-03-29 2013-03-29
US61/853,163 2013-03-29
PCT/US2014/032177 WO2014160940A2 (en) 2013-03-29 2014-03-28 Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders

Publications (2)

Publication Number Publication Date
AU2014240950A1 AU2014240950A1 (en) 2015-10-22
AU2014240950B2 true AU2014240950B2 (en) 2018-11-01

Family

ID=51625685

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014240950A Ceased AU2014240950B2 (en) 2013-03-29 2014-03-28 Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders

Country Status (7)

Country Link
US (6) US9371302B2 (de)
EP (1) EP2978422A4 (de)
JP (1) JP6532860B2 (de)
CN (2) CN105209037A (de)
AU (1) AU2014240950B2 (de)
CA (1) CA2908505A1 (de)
WO (1) WO2014160940A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209037A (zh) 2013-03-29 2015-12-30 雅沃科学有限责任公司 用于治疗癌症、神经障碍和纤维化病症的脂类呋喃、吡咯和噻吩化合物
US20170312246A1 (en) * 2016-04-27 2017-11-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis
KR102221789B1 (ko) * 2019-06-27 2021-03-02 재단법인대구경북과학기술원 2-펜틸퓨란을 유효성분으로 함유하는 퇴행성 뇌질환 치료용 조성물
CN110859836B (zh) * 2019-11-29 2022-04-15 南京林业大学 灵菌红素在制备淋巴管肌瘤病细胞增殖抑制剂中的应用
WO2022150415A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004211A1 (en) * 2003-06-30 2005-01-06 Kaohsiung Medical University Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds
US7037937B2 (en) * 2001-04-20 2006-05-02 Parker Hughes Institute Cytotoxic compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4427693A (en) * 1981-08-05 1984-01-24 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α,α-bis (polyhalomethyl)-2-thiophenemethanamines
CA1339784C (en) 1988-06-23 1998-03-31 Shinya Inoue Pyrrolecarboxylic acid derivatives
FR2678614A1 (fr) * 1991-07-03 1993-01-08 Pharmascience Lab Compose presentant une activite en tant qu'inhibiteur de la collagenase et medicament le contenant.
US5514709A (en) 1993-10-25 1996-05-07 Conkle & Olsten Lipidic furans and retinol palmitate compositions useful for skin therapeutics
US5468490A (en) 1993-10-25 1995-11-21 Conkle & Olesten Lipidic furans useful for skin therapeutics
WO2000000486A1 (en) 1998-06-29 2000-01-06 Biochem Pharma Inc. Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
US6166003A (en) * 1999-02-17 2000-12-26 Lkt Laboratories, Inc. Heterocyclic compounds for cancer chemoprevention
FR2798667B1 (fr) 1999-09-22 2001-12-21 Pharmascience Lab Procede d'extraction des composes furaniques et alcools gras polyhydroxyles de l'avocat, composition a base de et utilisation de ces composes en therapeutique, cosmetique et alimentaire
WO2003022838A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham Plc Pyridine substituted furan derivatives as raf kinase inhibitors
US6994875B2 (en) * 2002-07-29 2006-02-07 Laboratoires Expanscience Process for obtaining a furan lipid-rich unsaponifiable material from avocado
US20060018937A1 (en) 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20050124684A1 (en) * 2003-08-29 2005-06-09 Ying Du 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production
FR2870740B1 (fr) * 2005-03-21 2008-06-13 Expanscience Sa Lab Utilisation d'alkyle furannes pour le traitement cosmetique de la cellulite
FR2870742B1 (fr) 2004-05-28 2008-03-14 Expanscience Laboratoires Sa Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement du diabete, de l'obesite et pour le traitement cosmetique de la cellulite et de la surcharge ponderale
ATE462431T1 (de) 2004-05-28 2010-04-15 Expanscience Lab Verwendung von furanalkylen zur herstellung eines arzneimittels für die behandlung von adipositas sowie kosmetische behandlung von übergewicht
WO2006004759A2 (en) 2004-06-29 2006-01-12 Mcclellan Stephanie N Topical compositions for anti-aging
FR2889956B1 (fr) 2005-08-30 2012-04-20 Expanscience Lab Utilisation d'au moins un 2-alkyle furane, a titre de principe actif depigmentant ou eclaircissant
WO2007032591A1 (en) * 2005-09-13 2007-03-22 Industry-Academic Cooperation Foundation, Yeungnam University Composition comprising 1-furan-2-yl-3-pyridin-2-yl-pr0pen0ne having anti-angiogenic activity and cancer growth inhibitory activity
EP1939191A1 (de) * 2006-12-28 2008-07-02 Neuropharma S.A. Furanderivate, Syntheseverfahren und Verwendungen davon
JP2008201003A (ja) 2007-02-20 2008-09-04 Canon Inc インクジェット記録装置及びその記録ヘッド回復方法
EP3025714B9 (de) 2007-09-14 2020-11-18 Biogen MA Inc. Zusammensetzungen und verfahren zur behandlung von progressiver multifokaler leukoenzephalopathie (pml)
US20120295965A1 (en) * 2009-12-31 2012-11-22 Huayun Deng Fused thiophenes as dual inhibitors of egfr/vegfr and their use in the treatment of cancer
CN105209037A (zh) 2013-03-29 2015-12-30 雅沃科学有限责任公司 用于治疗癌症、神经障碍和纤维化病症的脂类呋喃、吡咯和噻吩化合物
US20170312246A1 (en) 2016-04-27 2017-11-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037937B2 (en) * 2001-04-20 2006-05-02 Parker Hughes Institute Cytotoxic compounds
US20050004211A1 (en) * 2003-06-30 2005-01-06 Kaohsiung Medical University Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds

Also Published As

Publication number Publication date
AU2014240950A1 (en) 2015-10-22
JP6532860B2 (ja) 2019-06-19
WO2014160940A3 (en) 2014-12-31
CN105209037A (zh) 2015-12-30
US11058663B2 (en) 2021-07-13
US20210137876A1 (en) 2021-05-13
CN111285841A (zh) 2020-06-16
US11833129B2 (en) 2023-12-05
US20200237709A1 (en) 2020-07-30
WO2014160940A2 (en) 2014-10-02
US20160263080A1 (en) 2016-09-15
US9371302B2 (en) 2016-06-21
US9814694B2 (en) 2017-11-14
JP2016515585A (ja) 2016-05-30
US20140309274A1 (en) 2014-10-16
CA2908505A1 (en) 2014-10-02
US20180050013A1 (en) 2018-02-22
EP2978422A4 (de) 2017-04-05
US10525031B2 (en) 2020-01-07
US20180360798A1 (en) 2018-12-20
EP2978422A2 (de) 2016-02-03
US10085962B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
US11833129B2 (en) Thiophene compound for treatment of exfoliating glaucoma
TWI612040B (zh) 作爲選擇性雌激素受體降解子（ｓｅｒｄ）之化合物及組合物
WO2021169963A1 (zh) 芳香类化合物及其在制备抗肿瘤药物中的应用
CN102574843B (zh) 抗纤维化剂的稠环类似物
CN109311839A (zh) 甲胺衍生物作为赖氨酰氧化酶抑制剂用于治疗癌症
UA123905C2 (uk) Спіро[3h-індол-3,2'-піролідин]-2(1h)-онові сполуки та похідні як інгібітори мdm2-p53
CN105523955B (zh) 化合物及其在制备药物中的用途
CA2531020C (en) Cannabinoid receptor modulator
CN102389409A (zh) Trp-p8活性化合物和治病性治疗方法
JP2021531249A (ja) 老化細胞除去組成物及びその使用
JP2021512060A (ja) 神経系疾患を治療するための化合物及びその応用
JP2007530427A (ja) 細胞毒性作用を有するコンブレタスタチン誘導体
JPH1067774A (ja) ベンゾチオフェン化合物ならびにその使用法および製剤
CN110981803B (zh) 一种抗肿瘤化合物及其合成方法与应用
JP4786147B2 (ja) カンナビノイド受容体調節剤
CA2546647C (en) Antidiabetic compounds comprising benzofuran and benzothiophene derivatives
WO2017170859A1 (ja) ビスアリール誘導体及びその医薬用途
TW201716390A (zh) 化合物、組成物及方法
JP2023513797A (ja) Ｕｌｋ１／２阻害剤による単剤療法および併用療法
JP2022051171A (ja) オートファジー阻害剤
CN115215821A (zh) 木脂素衍生物、其制备方法及用途
TW201343610A (zh) ｍＧｌｕ ２／３拮抗劑
EP3019472A1 (de) Tricyclische pyrrolverbindungen, deren herstellung und verwendung in medikamenten
JP2008143793A (ja) 新規ビフェノール誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired